
| Verifiedfields: | changed |
| Watchedfields: | changed |
| Verifiedrevid: | 458279808 |
| Iupac Name: | [(2''R'')-2,3-Dihydroxypropyl] 2-trimethylazaniumylethyl phosphate |
| Image Class: | skin-invert-image |
| Image Class2: | bg-transparent |
| Legal Status: | OTC |
| Cas Number: | 28319-77-9 |
| Unii: | 60M22SGW66 |
| Atc Prefix: | N07 |
| Atc Suffix: | AX02 |
| Chebi: | 55397 |
| Pubchem: | 657272 |
| Chemspiderid: | 571409 |
| Chembl: | 1567463 |
| Smiles: | [O-]P(=O)(OC[C@H](O)CO)OCC[N+](C)(C)C |
| Stdinchi: | 1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1 |
| Stdinchikey: | SUHOQUVVVLNYQR-MRVPVSSYSA-N |
| C: | 8 |
| H: | 20 |
| N: | 1 |
| O: | 6 |
| P: | 1 |
L-α-Glycerophosphorylcholine (alpha-GPC, choline alfoscerate, sn-glycero-3-phosphocholine) is a natural choline compound found in the brain. It is also a parasympathomimetic acetylcholine precursor[1] which has been investigated for its potential for the treatment of Alzheimer's disease[2] and other dementias.[3]
Alpha-GPC rapidly delivers choline to the brain across the blood–brain barrier and is a biosynthetic precursor of acetylcholine. It is a non-prescription drug in most countries. The FDA determined that intake of no more than 196.2 mg/person/day is considered generally recognized as safe (GRAS).[4]
Industrially, alpha-GPC is produced by the chemical or enzymatic deacylation of phosphatidylcholine enriched soya phospholipids followed by chromatographic purification. Alpha-GPC may also be derived in small amounts from highly purified soy lecithin as well as from purified sunflower lecithin.[5] [6]
A retrospective cohort study involving 12 million participants in South Korea found that α-GPC users had a higher risk of stroke (46 % higher). The authors suggested that one possible explanation is that dysbiosis may lead to α-GPC being metabolized into trimethylamine (TMA) in the gastrointestinal tract, and then to trimethylamine N-oxide (TMAO) in the liver, which has implications for cardiovascular health. However, they also noted that the study could be influenced by confounding variables, as α-GPC is often prescribed to individuals with preexisting health risks.[7]
A later systematic review and meta-analysis criticized the statistical analysis of the South Korean cohort study, describing it as questionable and imprecise. The review concluded that α-GPC has a favorable safety and tolerability profile and is effective in improving cognitive function and daily living in patients with dementia disorders of neurological origin, adult-onset vascular dementia, and Alzheimer’s disease.[8]